Results 11 to 20 of about 41,988 (210)

Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication:an exploratory trial [PDF]

open access: yes, 2011
Background. Although antipsychotic medication is the first line of treatment for schizophrenia, many service users choose to refuse or discontinue their harmacological treatment.
Hutton, P.   +49 more
core   +1 more source

Hyperprolactinaemia and Antipsychotic Drug Use : The Benefits of Prolactin Screening for Mental Health Patients [PDF]

open access: yes, 2006
Hyperprolactinaemia is associated with drugs used in the field of Mental Health to treat psychosis (antipsychotic). This has been found to be affecting a significant number of service users taking this medication.
Shaw, Michael, Michael Shaw
core   +2 more sources

The diagnostic dilemma in a patient with neuroleptic malignant syndrome during the COVID‐19 pandemic: A significant increase in acute phase reactants

open access: yesClinical Case Reports, 2023
Key Clinical Message In some patients, neuroleptic malignant syndrome is accompanied significant high levels of erythrocyte sedimentation rate (ESR), C‐reactive protein (CRP).
Forouzan Elyasi   +5 more
doaj   +1 more source

Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? [PDF]

open access: yes, 2012
Background: Little is known about the factors influencing treatment choice in psychosis, the majority of this work being conducted with specialists (consultant) in psychiatry.
Nwachukwu Izu   +73 more
core   +4 more sources

Adjunctive antidepressive pharmacotherapy in schizophrenia patients

open access: yesEuropean Psychiatry, 2021
Depressive symptoms during long-term course of schizophrenia constitute an important and frequent clinical problem. They may occur either as stand-alone major depressive episodes (MDEs) or as part of the schizophrenic negative syndrome.
M. Zink
doaj   +1 more source

The therapeutic relationship and adherence to antipsychotic medication in schizophrenia [PDF]

open access: yes, 2012
OBJECTIVE: Previous research has shown that a better therapeutic relationship (TR) predicts more positive attitudes towards antipsychotic medication, but did not address whether it is also linked with actual adherence.
McCabe, R   +68 more
core   +2 more sources

Comparison of droperidol and haloperidol for acute agitation in the emergency department: A retrospective cohort study [PDF]

open access: yesMental Health Clinician
Introduction To compare the effectiveness of droperidol and haloperidol for acute agitation in the emergency department. Methods Data from electronic health records were collected from January 1, 2022, to August 25, 2023, across 6 emergency departments ...
Francesca DiGuglielmo, PharmD   +4 more
doaj   +1 more source

Challenges in schizoaffetive disorder therapeutic – a case report of a patient with hiperprolactinemia

open access: yesEuropean Psychiatry, 2021
Introduction The only FDA approval therapeutic for schizoaffective disorder is paliperidone. Hiperprolactinemia is one of the most frequent side effects induced by first generation antipsychotics (FGA) or by second generation antipsychotic (SGA), such ...
D. Rodrigues   +3 more
doaj   +1 more source

Antipsychotics for irritability in children with Autism Spectrum Disorders

open access: yesEuropean Psychiatry, 2022
Introduction Autism is a neurodevelopmental disorder characterized by qualitative impairments in social interaction, communication, and restricted and repetitive behaviors [1]. Despite of these symptoms, some patients present different manifestations of
V. Muñoz Martinez   +2 more
doaj   +1 more source

Dosage of antipsychotics in China routine practice

open access: yesEuropean Psychiatry, 2021
Introduction The antipsychotic dosage of Chinese schizophrenia patients has rarely been studied, although nonstandard dosage has impact on prognosis. Objectives To describe the dosage of antipsychotics in China routine practice.
T. Zhang, R. Chi, T. Wu, Y. Xu, W. Dong
doaj   +1 more source

Home - About - Disclaimer - Privacy